Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.59 |
| ▸ | PIP5K1C | O60331 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | SCN4A | P35499 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7284884 | 0.91 | CYP3A4 (0.67) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL1913966 | 0.87 | KCNH2 (0.64) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL2488566 | 0.83 | CYP3A4 (0.65) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL614629 | 0.83 | KCNH2 (0.59) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL21709931 | 0.83 | KCNH2 (0.63) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL11098027 | 0.83 | CYP3A4 (0.65) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL2245983 | 0.83 | KCNH2 (1.00) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL10106162 | 0.83 | KCNH2 (0.59) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL21186214 | 0.81 | CYP3A4 (0.56) | KCNH2CYP3A4RAB9AMAPTHTT | |
| SCHEMBL9722735 | 0.80 | CYP3A4 (0.62) | KCNH2CYP3A4RAB9AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | claimed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | claimed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | claimed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | claimed |
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | HTT, ATXN2, ATXN2L | KCNH2 1471/4885CYP3A4 4340/4885RAB9A 809/4885 |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | HTT, ATXN2, ATXN2L | KCNH2 1471/4885CYP3A4 4340/4885RAB9A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.